Amgen stock tumbles after earnings report
Editor’s note: This article was updated at 8:35 a.m. on April 28 with up-to-date information on Amgen’s stock price. Amgen’s shares fell nearly 8% following the company’s April 27 release of its first quarter 2021 earnings, which saw a decline in both revenue and net income compared to a year earlier. Amgen is headquartered in Read More →
Read More →Amgen announces $721M acquisition
Amgen reported its second major acquisition of the month, as the Thousand Oaks-based firm announced March 30 that it will acquire Rodeo Therapeutics Corporation, a privately held biotech company based in Seattle. The deal is worth more than $700 million, $55 million of which will be paid upfront, with up to $666 million more in Read More →
Read More →Amgen to buy cancer treatment biotech firm for $1.9B
Thousand Oaks-based Amgen, one of the biggest biotech companies in the world, will get bigger with the $1.9 billion acquisition of Five Prime Therapeutics, a clinical-stage biotech company developing stomach cancer therapies. Amgen announced the acquisition March 4 and the deal is expected to close by the end of the second quarter of 2021. Under Read More →
Read More →Conejo Valley braces for Amgen layoffs
Biotech giant Amgen is in the process of laying off hundreds of workers, including as many as 100 at its Thousand Oaks headquarters. According to a spokesperson for the company, approximately 500 workers will be let go beginning April 2, with fewer than 20% of those workers located in Thousand Oaks. Amgen employs around 22,000 Read More →
Read More →Amgen to lay off hundreds, including in Thousand Oaks
Biotech giant Amgen is in the process of laying off hundreds of workers, including as many as 100 at its Thousand Oaks headquarters. According to a spokesperson for the company, approximately 500 workers will be let go beginning April 2. Less than 20% of those workers are located in Thousand Oaks. Amgen employs around 22,000 Read More →
Read More →Amgen reports rising revenue, warns of flat 2021
Amgen, one of the world’s largest biotech companies, saw rising revenue in the fourth quarter of 2020, but the COVID-19 pandemic could dampen the outlook for the company and its investors in 2021, according to earnings released Feb. 2. The Thousand Oaks-based biotech firm had $6.6 billion in revenue in the fourth quarter, a 7% Read More →
Read More →Amgen joins new cooperative trials for COVID treatment
With COVID-19 continuing to surge across the globe, a coalition of pharmaceutical companies including Thousand Oaks-based Amgen has announced a joint trial for new coronavirus treatments. Amgen, along with Takeda and UCB, are now collaborating to study methods of treatment for patients who are hospitalized due to COVID-19, the three companies announced. The trial enrolled Read More →
Read More →
Sponsored content:
2015-2016 Giving Guide
